<?xml version="1.0" encoding="UTF-8"?>
<p>Published observations in non‐pregnant patients have shown that non‐steroidal anti‐inflammatory drugs (NSAIDs), such as ibuprofen, can cause progression of pulmonary disease. This relationship has been observed in bacterial pulmonary infections. Experimental data suggest that NSAIDs alter the function of neutrophils and delay bacterial clearance and inflammation resolution
 <xref rid="uog22049-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="uog22049-bib-0004" ref-type="ref">4</xref>. Observational data suggest an association between exposure to NSAIDs and the occurrence of pleuropulmonary complications (pleural empyema, excavation and abscess). Similar observations have also been made in a small group of young people taking ibuprofen for COVID‐19 symptoms
 <xref rid="uog22049-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="uog22049-bib-0004" ref-type="ref">4</xref>. As a result, French health officials have issued a precaution regarding the use of NSAIDs, including aspirin. This has started an international debate among healthcare professionals regarding the usage of NSAIDs, primarily ibuprofen, in patients with COVID‐19
 <xref rid="uog22049-bib-0005" ref-type="ref">5</xref>. The Spanish Ministry of Health has stated that there is no evidence that ibuprofen (or other NSAIDs) could worsen SARS‐CoV‐2 infection. However, it stated that ibuprofen might mask the symptoms of infection, therefore delaying diagnosis
 <xref rid="uog22049-bib-0006" ref-type="ref">6</xref>. The Royal College of Obstetricians and Gynaecologists in the UK recommends paracetamol for COVID‐19 symptoms
 <xref rid="uog22049-bib-0007" ref-type="ref">7</xref>.
</p>
